Comparison of clinical characteristics between MDS patients according to the STAT3 mutation status
| Variable . | MDS with STAT3 mutation, n = 18 . | MDS without STAT3 mutation, n = 349 . | P . |
|---|---|---|---|
| Age, years (median, range) | 69 (27-70) | 66 (56-72) | .07 |
| Sex, % | |||
| Male | 59 | 56 | .6 |
| Female | 41 | 44 | |
| White blood cell count, ×109/L (median, IQR) | 5.1 (2.1-13.5) | 11.9 (2.7-25.7) | .04 |
| Absolute neutrophil count, ×109/L (median, IQR) | 1.23 | 4.41 (1-6.8) | ≤.001 |
| Hemoglobin, g/dL (mean ± SD) | 9.3 ± 1.9 | 9.9 ± 1.3 | .180 |
| Mean corpuscular volume, fL (median, IQR) | 95 (85-99) | 94 (86-104.8) | .875 |
| Platelets, ×109/L (median, IQR) | 139 (22-171) | 126 (24-186) | .743 |
| BM cellularity, % (median, IQR) | 43 (22-61) | 61 (45-90) | .034 |
| Abnormal cytogenetics, % | 52 | 51 | .9 |
| Patients with chromosome 7 abnormality, % | 32 | 9 | .09 |
| IPSS* | |||
| Low/intermediate-1 | 44 | 66 | .074 |
| Intermediate-2/high | 56 | 34 |
| Variable . | MDS with STAT3 mutation, n = 18 . | MDS without STAT3 mutation, n = 349 . | P . |
|---|---|---|---|
| Age, years (median, range) | 69 (27-70) | 66 (56-72) | .07 |
| Sex, % | |||
| Male | 59 | 56 | .6 |
| Female | 41 | 44 | |
| White blood cell count, ×109/L (median, IQR) | 5.1 (2.1-13.5) | 11.9 (2.7-25.7) | .04 |
| Absolute neutrophil count, ×109/L (median, IQR) | 1.23 | 4.41 (1-6.8) | ≤.001 |
| Hemoglobin, g/dL (mean ± SD) | 9.3 ± 1.9 | 9.9 ± 1.3 | .180 |
| Mean corpuscular volume, fL (median, IQR) | 95 (85-99) | 94 (86-104.8) | .875 |
| Platelets, ×109/L (median, IQR) | 139 (22-171) | 126 (24-186) | .743 |
| BM cellularity, % (median, IQR) | 43 (22-61) | 61 (45-90) | .034 |
| Abnormal cytogenetics, % | 52 | 51 | .9 |
| Patients with chromosome 7 abnormality, % | 32 | 9 | .09 |
| IPSS* | |||
| Low/intermediate-1 | 44 | 66 | .074 |
| Intermediate-2/high | 56 | 34 |
Boldface indicates significant P values.
BM, bone marrow; IPSS, International Prognostic Scoring System; IQR, interquartile range; SD, standard deviation.
Forty-eight patients with MDS/MPN disease were excluded from this subanalysis.